Nordic Science Investments co-leads CubaseBio's €3.9M funding round
CubaseBio, a biotechnology company founded by pioneers in spatial biology, has secured €5.9 million in blended financing. The funding comprises a €2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and €3.9 million in private capital and convertibles from Nordic Science Investments (NSI), Voima Ventures, Illumina Ventures, Almi Invest, Life Science Invest and several undisclosed private investors from the genomics technology space. Voima and NSI, two Nordic-based deeptech and life science investors, served as the lead investors.
The funding will be used to accelerate the technology development and commercialization of the company's next-generation spatial transcriptomic technology. Unlike conventional 2D spatial techniques, which are limited to thin tissue sections, CubaseBio's technology enables true three-dimensional analysis at scale. This technology provides researchers with unprecedented insights into complex 3D tissue structures.
CubaseBio was founded in 2024 by Malte Kuhnemund, Xiaoyan Qian, Toon Verheyen and Paulius Mielinis. Among the scientific advisory co-founders are Joshua Weinstein (Assistant Professor of Molecular Engineering at UChicago) and Björn Högberg (Professor and head of the Department of Medical Biochemistry and Biophysics at the Karolinska Institute).
Malte Kuhnemund, the CEO of CubaseBio, commented: "Biology is 3-dimensional. We want to enable measuring it in that way. We are thrilled to be backed by strong life science tech investors and the European innovation council that awarded our company for the high scalability and disruptiveness of our technology."
For more information, visit Biotech Newswire.
Newer
There are no newer news
